Related Experiment Video
Updated: Jan 28, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL
Shanmugapriya Thangavadivel1, John C Byrd2,3
1Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Abstract:
In this issue, Blombery and colleagues show that the chronic lymphocytic leukemia (CLL) cells bearing Gly101Val mutation confer resistance to venetoclax by reducing the affinity of BCL2 for venetoclax by 180-fold in cell lines and in patient cells. Detection of this mutation provides a potential biomarker for impending disease progression and an opportunity for targeted and combinational therapy to treat CLL.See related article by Blombery et al., p. 342.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Understanding the Self
Mutation, Gene Flow, and Genetic Drift
Understanding Memory

